Abstract:Outcomes for children and adolescents with newly diagnosed acute myeloid leukemia (AML) have only shown modest improvement over the past three decades. Additionally, outcomes for relapsed disease continue to be poor. As a result, there is a pressing need to optimize consolidation therapy to ensure deep and persistent remissions and prevent future relapse. In particular, the utility of bone and marrow transplant (BMT) for consolidation in pediatric AML has been debated for decades. A prior Children's Oncology Group (COG) study risk-stratified patients on the basis of cytogenetic alterations and demonstrated that consolidative BMT performed in first complete remission (CR1) improved long-term outcomes specifically in patients diagnosed with intermediate-risk disease, but found no survival benefit in patients with either low- or high-risk disease. Since then, whole genome and transcriptome sequencing have uncovered a large number of somatic mutations and cryptic fusions that carry prognostic significance in pediatric AML. Combining these molecular features with traditional cytogenetic risk stratification results in the re-classification of a significant number of patients. While this cytomolecular risk stratification is now being used in contemporary clinical trials (e.g., AAML1831/NCT04293562), the merits of consolidative BMT have not been rigorously re-assessed using these newly defined risk strata. To address this gap, we analyzed clinical and biological data from patients enrolled on COG phase 3 clinical trials AAML0531/NCT00372593 and AAML1031/NCT01371981. We filtered the resulting 2,024 patients to include those who had sufficient diagnostic data to ascertain their cytomolecular risk stratification. Additional inclusion criteria were achieving CR1; completing induction I, induction II, and intensification I; and undergoing BMT after intensification I, which was the recommended time point for BMT on both protocols. Our final analysis included 1,004 patients who met all inclusion criteria. BMT versus chemotherapy alone in CR1 was recommended based on indications provided by AAML0531 or AAML1031, which differ from one another (e.g., AAML1031 incorporated measurable residual disease). Clinical outcomes were assessed using Kaplan-Meier analysis and differences between groups were determined using log-rank testing. Clinical outcomes were superior for patients in the cytomolecular high-risk cohort who underwent BMT in CR1 relative to those who received chemotherapy alone. Specifically, high-risk patients who underwent BMT had a significantly improved five-year OS of 60.8 ± 9.3% (versus 41.3 ± 7.7%; p = 0.002) ( Fig. 1A) and DFS of 55.9 ± 9.4% (versus 30.6 ± 7.2%; p < 0.001) (data not shown). We also observed a decreased incidence of relapse in high-risk patients who received BMT, with a RR of 31.8 ± 8.8% relative to 64.5 ± 7.5% for patients in the chemotherapy only group (p < 0.001) ( Fig. 1B). Conversely, there was no difference in any of these outcome measures for patients in the low- and intermediate-risk groups who underwent BMT in CR1 versus receiving chemotherapy alone. Subsequent and ongoing analysis preliminarily indicates that while a subset of high-risk cytomolecular subtypes benefit from BMT in CR1, others do not. Increased availability of high-throughput sequencing has facilitated the identification of numerous molecular features that have prognostic importance in pediatric AML, leading to more accurate risk stratification and opportunities to better allocate patients to appropriate risk-adapted therapy. In this study, we demonstrate that incorporation of these molecular features into the traditional risk stratification schema significantly impacts the clinical indications for BMT as consolidation therapy in pediatric AML. Whereas BMT was previously found to benefit only those patients with intermediate-risk disease, our data suggest that patients with contemporary high-risk cytomolecular alterations benefit significantly from consolidative BMT. Notably, our current analysis does not yet address the potential bias that patients who reach BMT systematically differ from those patients who did not reach BMT (e.g., toxicity that precludes BMT), which we will address with multivariable analysis using BMT as a time varying exposure. These findings support the need for further prospective studies evaluating the role of BMT in high-risk pediatric AML.

Pediatric non-Hodgkin's lymphoma: clinical and biologic prognostic factors and risk allocation

The Prognostic and Risk Factors for Children With High‐Risk Mature B‐Cell Non‐Hodgkin's Lymphoma: A Retrospective Multicenter Study

[Clinical and Prognostic Analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].

Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study

Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making

Toward Inclusive Oncology: Challenges in the Therapy of Pediatric Non-B Non-Hodgkin Lymphomas

Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: A case report

Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia

[Outcomes of 104 Children with B-cell Non-Hodgkin Lymphoma].

Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report

Clinical study of 83 cases of pediatric Hodgkin lymphoma

Clinical Analysis of High-Risk Non-Hodgkin Lymphoma in Children

Use of Genomic Technologies to Identify Novel Genetic Abnormalities and Therapeutic Targets in Acute Lymphoblastic Leukemia.

B–NHL Cases in a Tertiary Pediatric Hematology—Oncology Department: A 20-Year Retrospective Cohort Study

[Clinical Analysis of 60 Children with Anaplastic Large Cell Lymphoma in a Single Center].

Clinical Outcome of 119 Children with Non-Hodgkin Lymphoma Treated in a Single Center in China

Anaplastic Large-cell Lymphoma in Children: State of the Art in 2023

[Efficacy of Short-Term and Intensive Chemotherapy for the Treatment of Childhood and Adolescent B Cell Non-Hodgkin's Lymphoma].

Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

[Clinical Features and Prognostic Factors of Children with Acute Lymphoblastic Leukemia in High-Risk Group].

[Prognostic Factors for Childhood Acute Non-Mature B-lymphoblastic Leukemia].